Interventional radiology

RenovoRx CEO Issues Update Letter to Shareholders

Retrieved on: 
torsdag, maj 30, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Doctor of Philosophy, Phase, Risk, Letter, University, Radiology, Death, Growth, TAMP, Cancer, Interventional radiology, Manuscript, Associate, Columbia University, History, Standard of care, Pharmaceutical industry

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
  • Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies.
  • In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer.
  • Your trust and confidence in RenovoRx have helped us build the remarkable company we have become, and one whose future has never been brighter.

Merit Medical Expands Embolics Portfolio with New Siege™ Vascular Plug and Bearing nsPVA Express™ Prefilled Syringe

Retrieved on: 
tisdag, maj 14, 2024
Foam, Blood, GEST, Embolization, Food, Education, FDA, Neoplasm, Radiology, Food and Drug Administration, PVA, Express, MMSI, MD, Research, Interventional radiology, Physician, Albany Medical Center, Intervention, Professor, Bearing, Prostatic artery embolization, Siege, Medical imaging

Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

Key Points: 
  • Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.
  • The latest additions to Merit’s Embolics portfolio, Siege Vascular Plug and Bearing nsPVA Express, complement a comprehensive offering of microsphere, particle, and gelatin foam products supported by a range of microcatheters, guide wires, and other enabling devices.
  • Embolization is a minimally invasive procedure where physicians implant devices or materials to occlude blood vessels or abnormal vascular channels.
  • The newly launched Bearing nsPVA Express is a 20-mL, vacuum-sealed syringe prefilled with Merit-manufactured Bearing nsPVA® Embolization Particles.

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

Retrieved on: 
tisdag, maj 21, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Doctor of Philosophy, Phase, University, Safety, Cancer, TAMP, JVIR, Interventional radiology, Manuscript, Medical imaging

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion (“TAMP”) therapy platform.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion (“TAMP”) therapy platform.
  • The data was published online in the peer-reviewed Journal of Vascular Interventional Radiology(“JVIR”) journal and will also be published in the print version.
  • RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide precise delivery to bathe the target solid tumor in chemotherapy.
  • We are awaiting final outcomes of the Phase III clinical trial, currently underway, to validate this benefit.”

Prospective Study Shares Early Clinical Experience with Shape Memory Polymer Vascular Plugs for Pelvic Venous Disease

Retrieved on: 
måndag, maj 13, 2024
General Health, Surgery, Medical Devices, Infectious Diseases, Health, Patient, Doctor of Philosophy, Female, European Journal, CPP, Leal, Vascular surgery, Magnetic resonance, Blood, Pelvic pain, PVD, Gynaecology, Interventional radiology, University of Navarra, Chronic pain, Woman, Pain, Multimedia, Memory, Birth control

Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the publication of a prospective observational study looking at the use of a single shape memory polymer plug, the IMPEDE-FX Embolization Plug, as the embolization agent to treat female pelvic venous disease (PVD).

Key Points: 
  • Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the publication of a prospective observational study looking at the use of a single shape memory polymer plug, the IMPEDE-FX Embolization Plug, as the embolization agent to treat female pelvic venous disease (PVD).
  • In this prospective, observational case series, Jose Ignacio Leal Lorenzo, MD, PhD, and lead author, reports encouraging outcomes in this early experience.
  • Early Experience on Embolisation of Female Pelvic Venous Disease With a Single Shape Memory Vascular Plug: A Prospective Magnetic Resonance Imaging Based Evaluation, published by Leal et al, is available via open access at https://authors.elsevier.com/a/1iutJ3rFXltnme .
  • For more information about Shape Memory Polymer for Pelvic Venous Disorders, visit www.shapemem.com/pelvic-health .

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Retrieved on: 
måndag, maj 6, 2024
Congress, Society, Interventional radiology, Mayo Clinic, Urology, Safety, American Urological Association, Poster, American Roentgen Ray Society, TSX, Prostate cancer, Prostate, Salvage therapy, Abdominal Radiology, Patient, ARRS, AUA, ECR, Clinical trial, SIR, Annual general meeting, JUA, BPH, Turku University Hospital, EAU

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation (“TULSA”) procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (“BPH”) patients have been made at major medical meetings already in 2024.

Key Points: 
  • “The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease,” said Arun Menawat, Profound’s CEO and Chairman.
  • “The various presentations made at AUA and other major medical conferences have highlighted TULSA’s clinical use across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer,” added Dr. Menawat.
  • “Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the TACT FDA regulatory study.
  • We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of TULSA among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses.”

AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

Retrieved on: 
måndag, maj 6, 2024
Research, Medical Devices, FDA, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Science, UCLA, Patient, Cancer, Bleeding, The Society, Assistant professor, Safety, IDE, Partnership, PERT, Pulmonary embolism, Acute, Associate, APEX, SCAI, Interventional radiology, Pharmaceutical industry

“Pulmonary emboli can be extremely dangerous and require effective and prompt action.

Key Points: 
  • “Pulmonary emboli can be extremely dangerous and require effective and prompt action.
  • In April 2024, the United States Food and Drug Administration (FDA) cleared the AlphaVac F1885 System for the treatment of PE.
  • “The results of the trial highlight the unique features of the AlphaVac device,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Scientific and Clinical Affairs.
  • The primary efficacy endpoint of the APEX-AV trial was the reduction in RV/LV ratio between baseline and 48 hours post-procedure.

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
tisdag, april 16, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, MVT, Sale, FDA, Pain, Interventional radiology, Patient, Phase, Risk, Ischemia, Pancreatic cancer, Prevalence, Thrombosis, LAPC, Radiology, MD, Venous thrombosis, Columbia University, Society of Interventional Radiology, Vein, SIR, Associate, TAMP, Coronary thrombosis, Medical imaging

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.
  • Clinical data was presented by David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York.
  • The data presentation highlighted that of the 25 patients randomized to the TAMP therapy, 6 failed to complete all 8 planned procedures due to thrombosis of the targeted arterial artery.
  • The first interim analysis in the Phase III TIGeR-PaC study was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study.

MedQuest Names Aalpen Patel Chief Clinical and Innovation Officer

Retrieved on: 
onsdag, april 10, 2024
General Health, Medical Devices, Other Health, Health, Health Technology, Society, University, Biomedical engineering, Bucknell University, Rutgers University, Informatics, AI, Teaching, Stevens Institute of Technology, Machine learning, Geisinger, MD Anderson Cancer Center, Human, Intelligence, Temple University Hospital, Engineering, Radiology, Patient, Physician, Medicine, Multimedia, Student, Interventional radiology, IBM, Nursing

MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.

Key Points: 
  • MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.
  • Dr. Patel joined on March 18 in a new role overseeing all functions related to clinical practices and innovation in product development and care delivery.
  • View the full release here: https://www.businesswire.com/news/home/20240408798629/en/
    MedQuest, a leading owner, operator, and manager of outpatient diagnostic imaging facilities in the U.S., has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer.
  • “MedQuest is committed to elevating the level of service we deliver to patients, physicians, and healthcare systems across the country.

University of Medicine and Health Sciences Celebrates Historic Match Day for Graduating Students

Retrieved on: 
måndag, april 22, 2024
Blog, University, Spectrum Health, Learning, Psychiatry, Emergency medicine, Dream, Anesthesiology, Internal medicine, Pediatrics, Pathology, History, UMHS, Obstetrics, Patient, Neurology, Child, Rehabilitation, Student, Detroit Medical Center, General surgery, Case Western Reserve University, COVID-19, Interventional radiology, Nursing

NEW YORK, April 22, 2024 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, celebrated one of its most successful Match Days in history. A remarkable 91% of first-time applicants secured residency placements, with graduating students earning positions in competitive programs across 14 medical specialties spanning 27 states, Puerto Rico, and Canada.

Key Points: 
  • In a message to students, UMHS President Warren Ross praised the school's historic 2024 Match results.
  • Graduating students secured residencies in highly competitive programs and will continue their training at esteemed teaching hospitals such as Case Western in Ohio and the University of Massachusetts Chan Medical School.
  • UMHS students matched into all six core specialties, including family medicine, internal medicine, obstetrics & gynecology, pediatrics, psychiatry, and surgery, as well as eight specialty fields, including anesthesiology, child neurology, diagnostic radiology, emergency medicine, neurology, pathology, and physical medicine and rehabilitation.
  • To learn more about the UMHS Class of 2024 Match Day and to see the complete 2024 Match results please visit https://www.umhs-sk.org/match-results .

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
tisdag, april 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.